The obstructive sleep apnea (OSA) market is being propelled by the rapid evolution of early detection and diagnostic tools. Technologies like home sleep apnea testing (HSAT), AI-powered applications, ...

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now ...

The FDA has expanded the approval of Eli Lilly's obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Lilly's obesity drug Zepbound gained US Food and Drug Administration approval on Dec. 20 in a new indication: moderate-to-severe obstructive sleep apnea. Why it matters: Patients with significant ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with regulators saying Friday that use of the drug is already covered ...

FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S. The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity — the first medication ...